CR20230052A - Combinaciones para el tratamiento de cáncer. - Google Patents

Combinaciones para el tratamiento de cáncer.

Info

Publication number
CR20230052A
CR20230052A CR20230052A CR20230052A CR20230052A CR 20230052 A CR20230052 A CR 20230052A CR 20230052 A CR20230052 A CR 20230052A CR 20230052 A CR20230052 A CR 20230052A CR 20230052 A CR20230052 A CR 20230052A
Authority
CR
Costa Rica
Prior art keywords
combinations
compound
relates
cancer
treatment
Prior art date
Application number
CR20230052A
Other languages
English (en)
Inventor
Gisela Schwab
Christian Scheffold
Ssucheng Jeff Hsu
Colin Chong
Peiwen Yu
Peter Lamb
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR20230052A publication Critical patent/CR20230052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a combinaciones que comprenden un inhibidor de punto de control y un inhibidor de c-Met, el Compuesto 1. La invención también se refiere a formas cristalinas de la base libre del Compuesto 1, así como también formas cristalinas de sales del Compuesto 1, en combinación con un inhibidor de punto de control. La invención también se refiere una composición farmacéutica que comprende estas combinaciones. La invención además se refiere a métodos para tratar un cáncer administrando el Compuesto 1 como un agente único o una combinación descrita en este documento.
CR20230052A 2020-07-31 2021-07-29 Combinaciones para el tratamiento de cáncer. CR20230052A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063059601P 2020-07-31 2020-07-31
US202063113556P 2020-11-13 2020-11-13
US202163148921P 2021-02-12 2021-02-12
PCT/US2021/043699 WO2022026706A1 (en) 2020-07-31 2021-07-29 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
CR20230052A true CR20230052A (es) 2023-04-11

Family

ID=77431400

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230052A CR20230052A (es) 2020-07-31 2021-07-29 Combinaciones para el tratamiento de cáncer.

Country Status (18)

Country Link
US (1) US20230301979A1 (es)
EP (1) EP4188376A1 (es)
JP (1) JP7847576B2 (es)
KR (1) KR20230059792A (es)
CN (1) CN116437954A (es)
AU (1) AU2021318134A1 (es)
BR (1) BR112023001792A2 (es)
CA (1) CA3186517A1 (es)
CL (1) CL2023000289A1 (es)
CO (1) CO2023001561A2 (es)
CR (1) CR20230052A (es)
GE (1) GEAP202616896A (es)
IL (1) IL300151A (es)
MX (1) MX2023001298A (es)
PE (1) PE20231369A1 (es)
PH (1) PH12023550160A1 (es)
TW (1) TW202220654A (es)
WO (1) WO2022026706A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
US20230326575A1 (en) * 2020-04-29 2023-10-12 Societe Des Produits Nestle S.A. System and method for providing fertility enhancing dietary recommendations in individuals with low testosterone
WO2021219579A1 (en) * 2020-04-29 2021-11-04 Société des Produits Nestlé S.A. System and method for providing fertility enhancing dietary recommendations in individuals with sperm conditions
JP2025509343A (ja) * 2022-03-07 2025-04-11 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用
EP4504264A4 (en) * 2022-04-08 2026-03-11 Global Cancer Tech Inc METHODS AND PRODUCTS FOR SCREENING AND TREATMENT OF GLIOBLASTOMA MULTIFORME AND OTHER CANCERS, INCLUDING BREAST CANCERS, USING A COMBINATION OF PI3KINASE INHIBITORS WITH CHECKPOINT INHIBITORS
CN120390641A (zh) * 2022-10-19 2025-07-29 西雅图儿童医院（Dba西雅图儿童研究所） 采用靶向小分子和抗靶向car t细胞的治疗方法
EP4665766A2 (en) * 2023-02-13 2025-12-24 LAVA Therapeutics N.V. Combination therapy comprising multispecific gamma delta tcr antibodies
EP4450972A1 (en) * 2023-04-21 2024-10-23 Fundación Instituto de Investigación Sanitaria de Santiago de Compostela In vitro method for predicting cancer patient response to pd-1 and/or pd-l1 inhibitors
CN117285533B (zh) * 2023-11-24 2024-01-30 四川省医学科学院·四川省人民医院 CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物
KR20260016691A (ko) * 2024-07-25 2026-02-04 서울대학교산학협력단 Tpst2 억제제 또는 ifngr1의 황산화 억제제를 포함하는 암의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
JP2019529476A (ja) * 2016-09-27 2019-10-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
BR112019015011A2 (pt) * 2017-01-20 2020-04-28 Exelixis Inc combinações de cabozantinibe e atezolizumabe para tratar câncer
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP4631505A3 (en) * 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Also Published As

Publication number Publication date
IL300151A (en) 2023-03-01
WO2022026706A1 (en) 2022-02-03
US20230301979A1 (en) 2023-09-28
MX2023001298A (es) 2023-02-22
PH12023550160A1 (en) 2023-09-18
CL2023000289A1 (es) 2023-09-01
BR112023001792A2 (pt) 2023-04-11
CO2023001561A2 (es) 2023-02-16
CA3186517A1 (en) 2022-02-03
JP2023536264A (ja) 2023-08-24
JP7847576B2 (ja) 2026-04-17
AU2021318134A1 (en) 2023-03-02
TW202220654A (zh) 2022-06-01
KR20230059792A (ko) 2023-05-03
EP4188376A1 (en) 2023-06-07
GEAP202616896A (en) 2026-04-27
CN116437954A (zh) 2023-07-14
PE20231369A1 (es) 2023-09-07

Similar Documents

Publication Publication Date Title
PH12023550160A1 (en) Combinations for the Treatment of Cancer
ZA202109010B (en) Compounds and methods for the treatment of covid-19
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12021500034A1 (en) Compounds useful in hiv therapy
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MX2024006094A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MY203645A (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
ZA202212095B (en) Il4i1 inhibitors and methods of use
TW200639159A (en) Treatment of pain
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2024015882A (es) Derivados de 3-(sulfonil o sulfonimidoil)prop-2-en-1-il]-2-oxo-1,2-dihidropiridina-3-carboxamida
MX2022015400A (es) Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette.
MX2025013372A (es) Inhibidores de gsk3\03b1 y metodos de uso de estos
CO2025012293A2 (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
MX2023009620A (es) Metodos terapeuticos.
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2023008796A (es) Métodos para el tratamiento del trastorno del habla en niños.